Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study

Table 3 Uni- and multivariate analysis exploring factors associated with increased risk of damage accrual

	Univariate analysis			Multivariate analysis
	∆-BODI ≥1 (n 36)	∆-BODI = 0 (n 153)	p	OR (95%CI)	p
Male gender	16 (44.4%)	76 (49.7%)	0.572
Age at enrolment	56.2 (42.9–62.0)	46.6 (35.4–53.1)	0.001	---	---
Disease duration	12.9 (7.1–17.5)	11.1 (5.4–21.2)	0.483
Major organ involvement^a	22 (61.1%)	72 (47.1%)	0,129
BDCAF at baseline	3 (0–5)	2 (0–5)	0.365
BDCAF at follow-up visit	3 (3–5)	3 (0–7)	0.188
Glucocorticoid duration	9.3 (2.2–12.3)	2.0 (0.7–6.0)	<0.001	1.150 (1.072–1.234)	<0.001
Immunosuppressant^b	24 (66.7%)	133 (86.9%)	0.004	0.201 (0.076–0.536)	<0.001
Cumulative n of immunosuppressants	2 (1–2)	2 (1–3)	0.162
At least 1 relapse	9 (25.0%)	20 (13.1%)	0.070	3.146 (1.085–9.120)	0.038
BODI score at baseline	1.0 (0–2.0)	1 (0–2)	0.579

In the univariate analysis, continuous variables are expressed as median (IQR) and categorical variables as number (%). Interval—age, disease duration and glucocorticoids refer to years. BODI, Behçet’s syndrome Overall Damage Index; BDCAF, Behçet’s Disease Current Activity Form; OR, odds ratio
^a Cumulative vascular, neurologic, gastrointestinal manifestations
^b Conventional and biologic immunosuppressants: azathioprine, methotrexate, cyclophosphamide, cyclosporine A, sulfasalazine, thalidomide, TNF-alpha inhibitors

ISSN: 1478-6362